Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Pre-Mkt 06-17 04:21:14 EDT

14.33

-0.27

-1.85%

High14.68	Low14.00	Vol1.54M
Open14.59	D1 Closing14.60	Amplitude4.62%
Mkt Cap753.27M	Tradable Cap704.27M	Total Shares52.57M
T/O22.11M	T/O Rate3.14%	Tradable Shares49.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":14.33,"timestamp":1781640000000,"preClose":14.6,"halted":0,"volume":1543472,"delay":0,"changeRate":-0.01849315068493148,"floatShares":49146600,"shares":52565600,"eps":-5.57,"marketStatus":"Pre-Mkt","change":-0.27,"latestTime":"06-17 04:21:14 EDT","open":14.59,"high":14.675,"low":14,"amount":22114121.319024,"amplitude":0.046233,"askPrice":16.82,"askSize":100,"bidPrice":11.44,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.57,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781703000000},"marketStatusCode":1,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":14.33,"postHourTrading":{"tag":"盘后","latestPrice":14.33,"preClose":14.33,"latestTime":"18:16 EDT","volume":7365,"amount":105540.17,"timestamp":1781648177057,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.326014847122757,"impliedVol":1.1204,"impliedVolPercentile":0.616},"requestUrl":"/m/hq/s/AVTX","defaultTab":"news","newsList":[{"id":"2643575153","title":"Avalo Therapeutics posts corporate deck highlighting IL-1β pipeline in hidradenitis suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643575153?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:17","pubTimestamp":1781608644,"startTime":"0","endTime":"0","summary":"Avalo outlined an IL-1β pipeline led by abdakibart  for moderate-to-severe hidradenitis suppurativa, citing positive Phase 2 topline data.LOTUS Phase 2 met its primary endpoint at week 16; combined HiSCR75 was 42.5% versus 25.6% for placebo .Combined HiSCR50 was 61.7% versus 40.7% for placebo ; dosing evaluated included 150 mg Q2W or 300 mg Q4W.Presentation cited about 500 patients studied across Phase 1 and 2; no adverse events related to neutropenia, serious infections, or opportunistic infections.AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, is expected to advance to IND in 1H 2027; cash runway projected into 2029 following USD 431.3 million financing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL8ljfKl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759760","title":"Avalo Therapeutics - to Submit Ind Application for Avtx-10 in First Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759760?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:05","pubTimestamp":1781607915,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O0AC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643597697","title":"Avalo Therapeutics Expands Pipeline With Avtx-010, a Long-Acting Next-Generation Anti-Il-1Β Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2643597697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643597697?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:05","pubTimestamp":1781607915,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O0AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643592547","title":"Avalo Therapeutics targets 1H 2027 IND for long-acting anti-IL-1β antibody AVTX-010","url":"https://stock-news.laohu8.com/highlight/detail?id=2643592547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643592547?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:04","pubTimestamp":1781607843,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics advanced AVTX-010, a long-acting next-generation anti-IL-1β antibody, to expand its inflammatory disease pipeline.IND filing planned for the first half of 2027; first-in-human studies expected to follow.No AVTX-010 clinical results were presented; the update focused on development timing.Strategy targets less frequent dosing to support adherence in chronic disease, with initial focus on hidradenitis suppurativa.Moves alongside recently reported positive Phase 2 topline results for lead drug abdakibart in hidradenitis suppurativa.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLrtFRs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","BK4588","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","AVTX","SG9999014039.USD","NDAQ","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","BK4112","IE00BN0W2T93.GBP","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643211773","title":"Kratos, AMD, CCEP, Avalo, WSM Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2643211773","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643211773?lang=en_us&edition=fundamental","pubTime":"2026-06-13 17:02","pubTimestamp":1781341327,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($KTOS) ), ( ($AMD) ), ( ($CCEP) ), ( ($AVTX) ) and ( ($WSM) ). Here is a breakdown of their recent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/kratos-amd-ccep-avalo-wsm-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/kratos-amd-ccep-avalo-wsm-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009356076.USD","LU1989764664.SGD","BK4529","BK4585","LU0868494708.USD","LU2089985449.USD","LU0081259029.USD","LU0889565833.HKD","LU1923623000.USD","LU1861558580.USD","AMDG","BK4534","AVTX","BK4575","LU1951200564.SGD","LU2860962120.EUR","IE00BMPRXQ63.HKD","LU2098885051.SGD","LU2092937221.SGD","BK4566","LU2041044095.USD","BK4178","LU0048578792.EUR","SG9999011175.SGD","LU2360108059.USD","BK4141","LU2237957811.SGD","WSM","LU1951198990.SGD","DAMD","LU0251132253.USD","LU0048584097.USD","LU0198837287.USD","LU1242518857.USD","LU1852331112.SGD","BK4177","IE00BQXX3D17.EUR","LU0997587240.USD","BK4603","BK4614","SG9999001424.SGD","LU2054465674.USD","AMDU","IE00BMPRXR70.SGD","LU0823434740.USD","BK4139","AMDW","BK4532","IE0004445239.USD","IE00BQXX3F31.USD","LU0823434583.USD","LU1316542783.SGD","LU1861559042.SGD","LU1119994140.HKD","LU1303367103.USD","LU2250418816.HKD","KTUP","SG9999003800.SGD","LU0786609619.USD","AMYY","LU1880398554.USD","BK4554","BK4543","BK4187","LU0174119429.USD","LU0942090050.USD","LU2931357623.SGD","IE00BMPRXN33.USD","CCEP","BK4605","AMUU","BK4588","BK4612","AMD","IE00BQXX3C00.GBP","BK4512","LU0170899867.USD","AMDD","LU0056508442.USD","LU1880398471.USD","LU0823421333.USD","LU2360106780.USD","LU0997586606.USD","LU0550127509.SGD","LU0274383776.USD","LU1242518931.SGD","LU0390134368.USD","LU0127658192.USD","LU0979878070.USD","AMDL","LU0109392836.USD","LU0082616367.USD","KTOS","LU0719512351.SGD","LU1803068979.SGD","LU0642271901.SGD","AMDY","LU2264538146.SGD","LU2458330243.SGD","LU2462591350.SGD","BK4573","LU1064131342.USD","LU2458330169.SGD","LU0868494617.USD","LU2355687059.USD","IE00B5949003.HKD","AMDS","LU1988902786.USD","LU2298321311.HKD","LU0823421416.USD","LU2242649171.HKD","LU2237957902.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643061290","title":"Avalo Therapeutics amends executive employment deals, boosts change-in-control severance terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2643061290","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643061290?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:08","pubTimestamp":1781294913,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics amended employment agreements for CEO Garry A. Neil, CFO Christopher Sullivan, CMO Mittie Doyle, and CBO Taylor Boyd, effective June 12, 2026.Outside a change-in-control window, termination without cause or for good reason triggers 12 months’ base-salary severance, or 18 months for Neil.Within three months before through 12 months after a change in control, severance shifts to 1x base salary plus 1x target bonus, or 1.5x salary for Neil.Change-in-control terminations also provide full acceleration of time-based equity awards; vested options remain exercisable for up to 12 months for Neil, Sullivan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL9kqyyZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642299231","title":"Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2642299231","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642299231?lang=en_us&edition=fundamental","pubTime":"2026-06-12 23:00","pubTimestamp":1781276427,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics'  lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said in a Friday research report.The results offer the pathway to relatively superior disease impact if consistency is retained in phase 3 studies starting H1 2027, BofA said.The brokerage said its investment case is founded on the company's differentiated IL-1Beta antibody for the inflammatory skin disease, a massive undertreated market, and a balance sheet runway through next major data readout in 2029.Avalo's reliance on a single asset as well as variability in placebo responses in hidradenitis suppurativa studies continue to pose key risks, according to the note.The brokerage said it initiated coverage of the stock with a buy rating and a price target of $35 per share.Price: 14.39, Change: +0.72, Percent Change: +5.23","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DBB","BK4007","AVTX","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642264125","title":"Avalo Therapeutics : Bofa Global Research Initiates Coverage With  Buy Rating and Price Objective $35.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2642264125","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642264125?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:17","pubTimestamp":1781259459,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nAZN4T20A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642261736","title":"Avalo Therapeutics initiated with a Buy at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642261736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642261736?lang=en_us&edition=fundamental","pubTime":"2026-06-12 17:51","pubTimestamp":1781257877,"startTime":"0","endTime":"0","summary":"BofA initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $35 price target The firm sees Avalo as a “cleaner, single-asset immunol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-initiated-with-a-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-initiated-with-a-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","AVTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642268681","title":"U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2642268681","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642268681?lang=en_us&edition=fundamental","pubTime":"2026-06-12 15:34","pubTimestamp":1781249644,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, OracleJune 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nL4N42K0GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULT","ORCU","RH","AMDW","BSX","AMDU","CVNA","AMDL","NTRA","PEP","BFH","CSCO","HQY","JBL","REG","SAIL","SMCI","SUNB","AMDG","MKTX","OCFC","MFIN","QCOM","AROW","GH","ETSY","DASH","PHIN","DAN","ORCL","AMDY","AMUU","SMYY","ANET","AMD","ADBE","MGM","KTOS","AMDS","FDX","CASY","AVTX","RHP","CDE","FTNT","IVT","QCMU","CASS","ADBG","CVNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431177","title":"Avalo Therapeutics shareholders approved amended employee stock purchase plan at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431177","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431177?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:20","pubTimestamp":1780950012,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics held its annual shareholder meeting on June 2, 2026.Shareholders backed amendments to the company’s 2016 employee stock purchase plan, clearing the updated plan for implementation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL4Vn0hv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640526964","title":"Avalo Therapeutics CMO Mittie Doyle disposes of 679 common shares for $10,864","url":"https://stock-news.laohu8.com/highlight/detail?id=2640526964","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640526964?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:08","pubTimestamp":1780344518,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Chief Medical Officer Doyle Mittie exercised stock options for 679 shares at USD 8.04 on May 28.He sold 679 shares at USD 16 in the same session.Mittie ended the day with 47,122 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL9w6W9g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle disposes of 679 common shares for $10,864","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637417863","title":"Avalo Therapeutics grants new hire option for 34,000 shares at $16.6 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2637417863","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637417863?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:01","pubTimestamp":1779480092,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics granted an inducement stock option covering 34,000 common shares to a new employee on May 21, 2026.The option exercise price was set at $16.6 per share, matching the stock’s closing price on the grant date.Vesting starts with 25% on the first anniversary of the employee’s start date, with the remainder vesting monthly over the next 36 months, subject to continued service.The award was issued under the company’s 2025 Inducement Award Plan.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL9QBY31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","SG9999014039.USD","BK4139","SG9999014005.SGD","NDAQ","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4588","BK4585","SG9999014013.SGD","BK4112","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210150020.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637341222","title":"Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637341222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637341222?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:01","pubTimestamp":1779480060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA7FVY4L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863864","title":"Avalo CMO Mittie Doyle disposes 3,000 shares for $56,280","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863864","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863864?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:11","pubTimestamp":1779221465,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 3,000 common shares on May 15 at USD 18.76.The sale followed the exercise of 3,000 stock options at USD 12.65 on the same day.Mittie ended the day with 3,622 common shares held directly.Derivative holdings included 128,625 stock options outstanding following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLb1BH8Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo CMO Mittie Doyle disposes 3,000 shares for $56,280","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635713219","title":"Avalo Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $35 From $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2635713219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635713219?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:14","pubTimestamp":1778753657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nAZN4SW89M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635358799","title":"U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2635358799","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635358799?lang=en_us&edition=fundamental","pubTime":"2026-05-14 15:24","pubTimestamp":1778743446,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology May 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cisc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4N41R0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIFG","MRVL","ANTX","DLLL","CSCL","DECK","AKAM","CVNA","EBAY","AEE","CMC","AVB","CLH","APGE","CVNX","CORZ","ANDG","ARVN","CMS","AFRM","DT","CIFR","CIFU","ASTH","AVTX","ASO","MRVU","CPT","CAKE","CSR","DELL","DTE","CARR","DOCS","CSCO","CGON","DMRA","ATLC","AN","AMGN","BXP","ARMK","CMP","CVNY","MVLL","AFRU","CSCS","CAVA","ABBV","ET"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635401780","title":"Avalo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635401780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635401780?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:31","pubTimestamp":1778679094,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAvalo Therapeutics Inc AVTX.OQ reported a quarterly adjusted loss of $1.13 per share for the quarter ended March","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q1TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786741","title":"Avalo Therapeutics Q1 net loss widens on increased R&D spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786741","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786741?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:12","pubTimestamp":1778670738,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Q1 net loss widens on increased R&D spendOverviewUS biotech firm's Q1 net loss missed analyst expectationsQ1 pretax profit missed analyst estimates, driven by higher R&D and admin e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q0HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786202","title":"Earnings Flash (AVTX) Avalo Therapeutics Posts Q1 Loss $0.98 a Share, vs. FactSet Est of $1.03 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786202?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:08","pubTimestamp":1778670507,"startTime":"0","endTime":"0","summary":"Earnings Flash (AVTX) Avalo Therapeutics Posts Q1 Loss $0.98 a Share, vs. FactSet Est of $1.03 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":0.1109},{"period":"1month","weight":-0.1922},{"period":"3month","weight":-0.0238},{"period":"6month","weight":-0.2422},{"period":"1year","weight":2.1085},{"period":"ytd","weight":-0.2109}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.063135},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.010519},{"month":3,"riseRate":0.272727,"avgChangeRate":0.280205},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.088879},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.046144},{"month":6,"riseRate":0.636364,"avgChangeRate":0.0013},{"month":7,"riseRate":0.5,"avgChangeRate":0.025049},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034606},{"month":9,"riseRate":0.6,"avgChangeRate":0.04604},{"month":10,"riseRate":0.6,"avgChangeRate":0.161359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.047903}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction